MicroRNA 558 (miR-558)

MicroRNA 558 (miR-558) is a short, non-coding RNA molecule that participates in the post-transcriptional regulation of gene expression by binding complementary sequences on target mRNAs, primarily to inhibit their translation or induce degradation[5]. MiR-558 is upregulated in certain cancers, including neuroblastoma and bladder cancer, where it acts as an oncogene. It promotes tumor growth, invasion, metastasis, and angiogenesis by enhancing the translation of key targets such as hypoxia-inducible factor 2 alpha (HIF-2α) in neuroblastoma[1][2] and heparanase (HPSE) in bladder and gastric cancer[3][5]. Its mechanisms involve direct binding to specific sites on target mRNAs, recruitment of Argonaute 2 (AGO2), and facilitation of translation initiation complex assembly. High miR-558 expression is associated with poorer prognosis in multiple cancer types and could serve as a prognostic biomarker for aggressive disease[1][3].

Other names

MIR558hsa-mir-558MIRN558

Not applicable—miRNAs themselves are not directly drug targets in clinical use, but can be targeted or mimicked with antisense oligonucleotides or miRNA mimics/inhibitors